Discover 27 paid clinical trials in Hattiesburg, Mississippi. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 27
Active & Responsive
Caris Biorepository Research Protocol
for
Cancer, Early Detection of Cancer, Minimal Residual Disease
Location: Hattiesburg MS, Mobile AL, Jackson MS, New Orleans LA,
Sponsor: Caris Science, Inc.
Sex: All
Age: 18+
Code: NCT01499394
Recruiting
Active & Responsive
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
Get alerts for new trials in your area by subscribing now
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
for
Multiple Myeloma
Location: Hattiesburg MS, Germantown TN, Atlanta GA, Nashville TN,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT05827016
Phase3, Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
for
Non-small Cell Lung Cancer
Location: Hattiesburg MS, Tyler TX, Houston TX, St. Petersburg FL,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT06561386
Phase3, Recruiting
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
for
Follicular Lymphoma
Location: Hattiesburg MS, Mobile AL, Newnan GA, Marietta GA,
Sponsor: Celgene
Sex: All
Age: 18+
Code: NCT06911502
Phase3, Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)